I think, Madam Chair, with great respect, CanSino was not at the heart of the Canadian strategy, by any means. It was a much more balanced approach. The task force, as Joanne and Mark indicated, recommended strongly for a diversified portfolio across both vaccine platforms and companies. At all times, a full-court press was put on all fronts. There was no effort made by anybody to privilege one company over another, and certainly not CanSino.
